MARATTO

article

A Multi-Omics Study Reveals Pathway-Level Insights and Predictive Biomarkers in Pediatric TB

Abstract

Background: Tuberculosis (TB) remains a global health threat, affecting over a million children under the age of 15 annually. Many children with TB do not receive treatment due to challenges in diagnosis. Methods: We performed a multi-omics analysis for pediatric TB by integrating plasma proteomics and metabolomics data from children with presumptive TB across four high-burden countries. Pathway enrichment analysis was conducted using multiGSEA to identify relevant immune and metabolic pathways. We also applied mixOmics and multiview approaches for diagnostic biomarker discovery and compared the performance of multi-omics signatures with those derived from single-omics datasets. Results: Enrichment analysis revealed several immune and metabolic pathways, including PTEN and RUNX2 regulation pathways, as well as arginine and proline metabolism, that were uniquely identified through data integration. While the multi-omics model showed marginal improvement over single-omics models, proteomics alone generally outperformed metabolomics and demonstrated greater potential for accurately classifying Confirmed TB versus Unlikely TB in children. Conclusion: These findings demonstrate the advantage of combining complementary molecular layers to gain a deeper understanding of disease mechanisms and highlight the potential of proteomics for improving pediatric TB diagnosis.

Research topics

  • Tuberculosis Research and Epidemiology
  • Metabolomics and Mass Spectrometry Studies
  • Diagnosis and treatment of tuberculosis

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.64898/2026.03.13.26348257

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.